This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mann, G. B. Articles by Buchanan, M. R. Search for Related Content PubMed PubMed Citation Articles by Mann, G. B. Articles by Buchanan, M. R. Social Bookmarking                            What's this?

Reliance on Hormone Receptor Assays of Surgical Specimens May Compromise Outcome in Patients With Breast Cancer

From the Department of Surgery and Pathology, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Australia

Address reprint requests to Bruce Mann, MBBS, PhD, FRACS, Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Parkville 3050, Australia; e-mail: bruce.mann{at}mh.org.au

PURPOSE: To assess the concordance of breast cancer immunohistochemical receptor assays on core biopsy and surgical specimens.

PATIENTS AND METHODS: We identified 100 patients whose core biopsy and definitive surgical specimens were processed in our hospital. New sections, with core and surgical specimens on the same slides, were stained for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) immunohistochemistry (IHC). Two pathologists assessed the sections independently. Raw scores and clinically significant groupings were compared.

RESULTS: Concordance for ER, PR, overall hormone receptor (HR), and HER-2 status was seen in 86%, 83%, 90%, and 80% of patients, respectively. The core was positive, while the surgical specimen was negative in 13%, 11%, 9%, and 1% of patients, respectively. Using a log-linear model, differences in ER, PR, and HER-2 staining were all in the direction of stronger staining in the cores, and were statistically significant. Nine percent (95% CI, 4.2% to 16.4%) of women in this group would have had endocrine therapy inappropriately withheld if management decisions were based on surgical specimen results alone.

CONCLUSION: ER and PR assays on core biopsy specimens are more reliable than assays on surgical specimens. Receptor IHC should be performed on core biopsy specimens to avoid patients with HR positive cancers not receiving appropriate hormonal therapy and being overtreated with systemic chemotherapy. Biopsy should be considered in patients with "receptor negative" cancer and recurrent disease.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A. Iverson, C. Gillett, P. Cane, C. D. Santini, T. M. Vess, L. Kam-Morgan, A. Wang, M. Eisenberg, C. M. Rowland, J. J. Hessling, et al. A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens J. Mol. Diagn., March 1, 2009; 11(2): 117 - 130. [Abstract] [Full Text] [PDF]

				T. Uematsu, M. Kasami, and S. Yuen Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings Radiology, March 1, 2009; 250(3): 638 - 647. [Abstract] [Full Text] [PDF]

				H. S. Rugo The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors Ann. Onc., January 1, 2008; 19(1): 16 - 27. [Abstract] [Full Text] [PDF]

				E A Rakha and I O Ellis An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens J. Clin. Pathol., December 1, 2007; 60(12): 1300 - 1306. [Abstract] [Full Text] [PDF]

				O. Tacca, F. Penault-Llorca, C. Abrial, M.-A. Mouret-Reynier, I. Raoelfils, X. Durando, J.-L. Achard, P. Gimbergues, H. Cure, and P. Chollet Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Oncologist, June 1, 2007; 12(6): 636 - 643. [Abstract] [Full Text] [PDF]

				Z. Hodi, J. Chakrabarti, A. H S Lee, J. E Ronan, C. W Elston, K. Leung Cheung, J. F R Robertson, and I. O Ellis The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast J. Clin. Pathol., March 1, 2007; 60(3): 299 - 302. [Abstract] [Full Text] [PDF]

				D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman, L. J. Goldstein, S. Martino, E. A. Perez, H. B. Muss, L. Norton, et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer JAMA, April 12, 2006; 295(14): 1658 - 1667. [Abstract] [Full Text] [PDF]

				G. B. Mann and M. R. Buchanan In Reply: J. Clin. Oncol., December 1, 2005; 23(34): 8918 - 8919. [Full Text] [PDF]